Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03744390
Recruitment Status : Recruiting
First Posted : November 16, 2018
Last Update Posted : December 2, 2020
Sponsor:
Information provided by (Responsible Party):
Groupe Francophone des Myelodysplasies

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 18, 2023
Estimated Study Completion Date : February 18, 2023